Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7232-7239

  Wenzler, Eric ^a   Gotfried, Mark H ^b   Loutit, Jeffrey S ^c   Durso, Stephanie ^c   Griffith, David C ^c   Dudley, Michael N ^c   Rodvold, Keith A ^a,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Pulmonary Associates   (United States)

^c Medicines Company   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAVANCE; MEROPENEM; UNCLASSIFIED DRUG; VABORBACTAM; ANTIINFECTIVE AGENT; BORONIC ACID DERIVATIVE; DRUG COMBINATION; SINGLE HETEROCYCLIC RINGS; THIENAMYCIN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CELL LEVEL; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ELIMINATION HALF-LIFE; EPITHELIAL LINING FLUID; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LUNG ALVEOLUS MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; THORAX PAIN; VOLUME OF DISTRIBUTION AT STEADY-STATE; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CHEMISTRY; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; LUNG; METABOLISM; MIDDLE AGED; RESPIRATORY MUCOSA;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BORONIC ACIDS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LUNG; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; RESPIRATORY MUCOSA; THIENAMYCINS;

EID: 84954552671     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01713-15     Document Type: Article

References (28)

1. Spellberg B, Bartlett JG, Gilbert DN. 2013. The future of antibiotics and resistance. N Engl J Med 368:299-302. http://dx.doi.org/10.1056/NEJMp1215093.
2. Livermore DM. 2011. British Society for Antimicrobial Chemotherapy Working Party on The Urgent Need: Regenerating Antibacterial Drug Discovery and Development. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 66:1941-1944.
3. Nordmann P, Naas T, Poirel L. 2011. Global spread of carbapenemase producing Enterobacteriaceae. Emerg Infect Dis 17:1791-1798. http://dx.doi.org/10.3201/eid1710.110655.
4. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. 2014. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58:654-663. http://dx.doi.org/10.1128/AAC.01222-13.
5. U.S. Department of Health and Human Services/Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-20 13-508.pdf
6. Drawz SM, Papp-Wallace KM, Bonomo RA. 2014. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58:1835-1846. http://dx.doi.org/10.1128/AAC.00826-13.
7. Olsen I. 2015. New promising β-lactamase inhibitors for clinical use. Eur J Clin Microbiol Infect Dis 34:1303-1308. http://dx.doi.org/10.1007/s10096-015-2375-0.
8. Toussaint KA, Gallagher JC. 2015. β-lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother 49:86-98. http://dx.doi.org/10.1177/1060028014556652.
9. Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN. 2015. Discovery of a cyclic boronic acid β-lactamase inhibitor (PRX7009) with utility versus class A serine carbapenemases. J Med Chem 58:3682-3692. http://dx.doi.org/10.1021/acs.jmedchem.5b00127.
10. Castanheria M, Becker HK, Rhomberg PR, Jones RN. 2014. Effect of the β-lactamase inhibitor RPX7009 combined with meropenem tested against a large collection of KPC-producing Enterobacteriaceae, abstr C-777. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society of Microbiology, Washington, DC.
11. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, Landman D. 2015. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59:4856-4860. http://dx.doi.org/10.1128/AAC.00843-15.
12. Griffith DC, Rubino CM, Loutit JS, Morgan EE, White D, Dudley MN. 2014. A phase 1 study of the safety, tolerability, and pharmacokinetics of a single dose of the beta-lactamase inhibitor RPX7009 alone, meropenem alone, and both in combination (Carbavance) in healthy adult subjects, abstr F-960. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society of Microbiology, Washington, DC.
13. Griffith DC, Rubino CM, Loutit JS, Morgan EE, White D, Dudley MN. 2014. A phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor RPX7009 alone, meropenem alone, and both in combination (Carbavance) TID for 7 days in healthy adult subjects, abstr 401. Abstr ID Week. Infectious Diseases Society of America, Arlington, VA.
14. Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. 2010. Pharmacokinetic-pharmacodynamic considerations in the design of hospitalacquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clin Infect Dis 51(Suppl 1):S103-S110.
15. Rodvold KA, George JM, Yoo L. 2011. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet 50:637-664. http://dx.doi.org/10.2165/11594090-000000000-00000.
16. Baldwin DR, Honeybourne D, Wise R. 1992. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrob Agents Chemother 36:1171-1175. http://dx.doi.org/10.1128/AAC.36.6.1171.
17. Rodvold KA, Gotfried MH, Still JG, Clark K, Fernandes P. 2012. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother 56:5076-5081. http://dx.doi.org/10.1128/AAC.00766-12.
18. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
19. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60: 532-538.
20. Baldwin DR, Wise R, Andrews JM, Ashby JP, Honeybourne D. 1990. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 3:886-890.
21. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. 2003. Pharmacokinetics of meropenem 0.5 and 2 g every 8 h as a 3-hour infusion. Pharmacotherapy 23:988-991.
22. Drusano GL, Hutchison M. 1995. The pharmacokinetics of meropenem. Scand J Infect Dis 96(Suppl):11-16.
23. Peleg AY, Salmon M. 2010. Meropenem, p 500-513. In Grayson ML (ed), Kucer's the use of antibiotics, 6th ed. American Society of Microbiology, Washington, DC.
24. Conte JE, Jr, Golden JA, Kelley MG, Zurlinden E. 2005. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem. Int J Antimicrob Agents 26:449-456. http://dx.doi.org/10.1016/j.ijantimicag.2005.08.015.
25. Allegranzi B, Cazzadori A, Di Perri G, Bonora S, Berti M, Franchino L, Biglino A, Cipriani A, Concia E. 2000. Concentrations of single-dose meropenem (1 g i.v.) in bronchoalveolar lavage and epithelial lining fluid. J Antimicrob Chemother 46:319-322. http://dx.doi.org/10.1093/jac/46.2.319.
26. Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. 2011. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 55: 1606-1610. http://dx.doi.org/10.1128/AAC.01330-10.
27. Frippiat F, Musuamba FT, Seidel L, Albert A, Denooz R, Charlier C, Van Bambeke F, Wallemacq P, Descy J, Lambermont B, Layios N, Damas P, Moutschen M. 2015. Modeled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother 70:207-216. http://dx.doi.org/10.1093/jac/dku354.
28. Felton TW, McCalman K, Malagon I, Isalska B, Whalley S, Goodwin J, Bentley AM, Hope WW. 2014. Pulmonary penetration of piperacillin and tazobactam in critically ill patients. Clin Pharmacol Ther 96:438-448. http://dx.doi.org/10.1038/clpt.2014.131.